Figures & data
Box 1. Drug summary.
Figure 1. rhASB plasma concentrations during and 2 h after the first infusion with the area under the plasma concentration-time curve (AUC0-t).
![Figure 1. rhASB plasma concentrations during and 2 h after the first infusion with the area under the plasma concentration-time curve (AUC0-t).](/cms/asset/b7d46251-3824-4c63-a588-5aa8e1285090/ieod_a_885833_f0001_b.jpg)
Table 1. Phase III study: summary of effect on primary and secondary endpoints.
Table 2. Summary of AEs during study weeks 1 – 48.
Table 3. Summary of study populations.